EGFR and non-small cell lung carcinoma: The NCT02864251 trial evaluated nivolumab plus chemotherapy versus chemotherapy alone in patients with EGFR-mutated NSCLC after progression on EGFR tyrosine kinase inhibitors and found no significant improvement in PFS with the combination therapy, although a trend favoring nivolumab was observed in specific subgroups [223].